This treatment also induced durable memory responses that protected against tumor re-emergence,21 illustrating the therapeutic potential of IL-2 agonists that selectively target CD25 on antigen-experienced effector T cells in the context of checkpoint inhibition for cancer immunotherapy. Here, IL2 is linked to cancer.